Gyre Therapeutics
GYRE
56 hedge funds and large institutions have $23.8M invested in Gyre Therapeutics in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 2 closing their positions.
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
27% more funds holding
Funds holding: 44 → 56 (+12)
1% more capital invested
Capital invested by funds: $23.6M → $23.8M (+$136K)
0.04% more ownership
Funds ownership: 3.47% → 3.51% (+0.04%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $14K
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$326K |
| 2 |
BlackRock
New York
|
+$298K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$112K |
| 4 |
State Street
Boston,
Massachusetts
|
+$110K |
| 5 |
BHCM
Brevan Howard Capital Management
St. Helier,
Jersey
|
+$107K |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$356K |
| 2 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$175K |
| 3 |
Barclays
London,
United Kingdom
|
-$126K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$67K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$55.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SAM
51
Smartleaf Asset Management
Boston,
Massachusetts
| $41 | – | – | – |
|
|
EP
52
Essential Partners
Rancho Santa Fe,
California
| $28 | +$31 | +4 | New |
|
|
MCM
53
MAI Capital Management
Independence,
Ohio
| $28 | +$31 | +4 | New |
|
|
CIAM
54
Caitong International Asset Management
Hong Kong
| $21 | +$23 | +3 | New |
|
|
EWA
55
EverSource Wealth Advisors
Birmingham,
Alabama
| $21 | +$23 | +3 | New |
|
|
56
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$175K | -24,800 | Closed |
|
|
AB
57
Amalgamated Bank
New York
| – | -$3K | -371 | Closed |
|
|
C
58
Covestor
London,
United Kingdom
| – | +$62 | +8 | +133% |
|
GYRE Hedge Fund Activity: Q1 2026 in Review
56 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2026, worth a combined $23.8M — up 0.57% from $23.6M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new GYRE positions and 2 closed out — a net gain of 13 holders — while 18 added to existing stakes and 11 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $326K. The largest seller was Morgan Stanley, cutting an estimated $356K.
- 56 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2026, up from 44 in Q4 2025.
- Funds reported $23.8M of Gyre Therapeutics stock for Q1 2026, up 0.57% quarter-over-quarter.
- 15 funds opened new Gyre Therapeutics positions in Q1 2026 and 2 closed out, a net change of +13 holders.
- The largest Gyre Therapeutics buyer in Q1 2026 was Goldman Sachs, an estimated $326K added.
- The largest Gyre Therapeutics seller in Q1 2026 was Morgan Stanley, an estimated $356K sold.
Based on aggregated 13F filings for Q1 2026.